When analoging is not enough: Scaffold discovery in medicinal chemistry

Expert Opinion on Drug Discovery

Volumn 5, Issue 2, 2010, Pages 123-134

  Zhao, Hongyu ^a   Akritopoulou Zanze, Irini ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Fragment based drug design; Scaffold discovery; Scaffold hopping; Structure based drug design

Indexed keywords

4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ACYL COENZYME A DESATURASE 1 INHIBITOR; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEPHALOSPORIN; CLOZAPINE; ENZYME INHIBITOR; EPOTHILONE B; HYDROCODONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDEGLITAZAR; IXABEPILONE; LANSOPRAZOLE; LIGAND; MACROPHAGE ELASTASE INHIBITOR; NICOTINAMIDE; OMEPRAZOLE; PANTOPRAZOLE; PENICILLIN G; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENETHYLAMINE; PHENTERMINE; PHOSPHATASE; PHOSPHODIESTERASE V INHIBITOR; PROTEIN INHIBITOR; RABEPRAZOLE; SILDENAFIL; STEROID; UNCLASSIFIED DRUG; VARDENAFIL;

CHEMICAL SCAFFOLD; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ERECTILE DYSFUNCTION; FRAGMENT BASED DRUG DESIGN; HUMAN; MEDICINAL CHEMISTRY; MOLECULAR DOCKING; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 75449116535     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903584874     Document Type: Review

References (57)

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-477
2. Jhoti H, Leach AR. Structure-based drug discovery. Springer, Dordrecht; 2007
3. Brown N, Jacoby E. On scaffolds and hopping in medicinal chemistry. Mini Rev Med Chem 2006;6:1217-1229
4. Schneider G, Schneider P, Renner S. Scaffold-hopping: how far can you jump? QSAR Comb Sci 2006;25:1162-1171
5. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 2007;6:211-219
6. Congreve M, Chessari G, Tisi D, et al. Recent developments in fragment-based drug discovery. J Med Chem 2008;51:3661-3680
7. Aronov AM, McClain B, Moody CS, et al. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. J Med Chem 2008;51:1214-1222
8. van der Horst E, Okuno Y, Bender A, et al. Substructure mining of GPCR ligands reveals activity-class specific functional groups in an unbiased manner. J Chem Inf Model 2009;9:348-360
9. Zhao H. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Drug Discov Today 2007;12:149-155
10. Oprea TI, Davis AM, Teague SJ, et al. Is there a difference between leads and drugs? A historical perspective. J Chem Info Comput Sci 2001;41:1308-1315
11. Proudfoot JR. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg Med Chem Lett 2002;12:1647-1650
12. Reich HJ, Cram DJ. Macro rings. XXXVII. Multiple electrophilic substitution reactions of [2.2] paracyclophanes and interconversions of polysubstituted derivatives. J Am Chem Soc 1969;91:3527-3533
13. Vieth M, Sutherland JJ. Dependence of molecular properties on proteomic family for marketed oral drugs. J Med Chem 2006;49:3451-3453
14. Lombardino JG, Lowe JA. The role of the medicinal chemist in drug discovery-then and now. Nat Rev Drug Discov 2004;3:853-862
15. Adams C, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Aff 2006;2:420-428
16. Warr WA. Fragment-based drug discovery. J Comput Aided Mol Des 2009;23:453-458
17. Keserü GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009;8:203-212
18. Fink T, Bruggesser H, Reymond JL. Virtual exploration of the small-molecule chemical universe below 160 Daltons. Angew Chem Int Ed Engl 2005;44:1504-1508
19. Schuffenhauer A, Ruedisser S, Marzinzik A, et al. Library design for fragment based screening. Curr Top Med Chem 2005;5:751-762
20. Orita M, Warizaya M, Amano Y, et al. Advances in fragment-based drug discovery platforms. Exp Opin Drug Discov 2009;4:1125-1144
21. Babaoglu K, Shoichet BK. Deconstructing fragment-based inhibitor discovery. Nat Chem Biol 2006;2:720-723
22. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004;3:301-317
23. Fuller JC, Burgoyne NJ, Jackson RM. Predicting druggable binding sites at the protein-protein interface. Drug Discov Today 2009;14:155-161
24. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl family proteins induces regression of solid tumours. Nature 2005;435:677-681
25. Wendt MD. Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction. Exp Opin Drug Discov 2008;3:1123-1143
26. Juin P, Geneste O, Raimbaud E, et al. Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim Biophys Acta 2004;1644:251-260
27. Petros AM, Dinges J, Augeri DA, et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem 2006;49:656-663
28. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006;16:127-136
29. Morphy R, Rankovic Z. Fragments, network biology and designing multiple ligands. Drug Discov Today 2007;12:156-160
30. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-359
31. Morphy R, Rankovic Z. The physicochemical challenges of designing multiple ligands. J Med Chem 2006;49:4961-4970
32. Card GL, Blasdel L, England BP, et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 2005;23:201-207
33. Artis DA, Lin JJ, Zhang C, et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci USA 2009;106:262-267
34. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-550
35. Schneider G, Neidhart W, Giller T, et al. "Scaffold-hopping" by topological pharmacophore search: a contribution to virtual screening. Angew Chem Int Ed Engl 1999;38:2894-2896
36. Xin Z, Zhao H, Serby MD, et al. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors. Bioorg Med Chem Lett 2008;18:4298-4302
37. Abreo M, Chafeev M, Chakka N, et al. WO 2005/011655; 2005
38. Liu G, Lynch JK, Freeman J, et al. Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors. J Med Chem 2007;50:3086-3100 (Pubitemid 47001252)
39. Zhao H, Guo Z. Medicinal chemistry strategies in follow-on drug discovery. Drug Discov Today 2009;14:516-522
40. Sandner P, Ziegelbauer K. Product-related research: how research can contribute to successful life-cycle management. Drug Discov Today 2008;13:457-463
41. Nicholas KT, Andrew SB, David B, et al. Sildenafil (VIAGRA™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett 1996;6:1819-1824
42. Haning H, Niewöhner U, Schenke T, et al. Imidazo[5,1-f][1,2, and 4]triazin-4 (3H)-ones, a new class of potent PDE 5 inhibitors. Bioorg Med Chem Lett 2002;12:865-868
43. Andricopulo AD, Salum1 LB, Abraham DJ. Structure-based drug design strategies in medicinal chemistry. Curr Top Med Chem 2009;9:771-790
44. Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 2005;4:649-663
45. Klebe G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 2006;11:580-594
46. Clark DE. What has computer-aided molecular design ever done for drug discovery? Exp Opin Drug Discov 2006;1:103-110
47. Jorgensen WL. Efficient drug lead discovery and optimization. Acc Chem Res 2009;42:724-733
48. Nuti E, Panelli L, Casalini F, et al. Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. J Med Chem 2009;52:6347-6361
49. Zaliani A, Boda K, Seidel T, et al. Second-generation de novo design: a view from a medicinal chemist perspective. J Comput Aided Mol Des 2009;23:593-602
50. Vieth M, Erickson J, Wang J, et al. Kinase inihibitor data modeling and de novo inhibitor design with fragment approaches. J Med Chem 2009;52:6456-6466
51. Bemis GW, Murcko MA. The properties of known drugs. 1. Molecular frameworks. J Med Chem 1996;39:2887-2893
52. Wilson RM, Danishefsky SJ. Small molecule natural products in the discovery of therapeutic agents: the synthesis connection. J Org Chem 2006;71:8329-8351
53. Borzilleri RM, Vite GD. Case history: discovery of ixabepilone (IXEMPRA™), a first-in-class epothilone analog for treatment of cancer. Ann Rep Med Chem 2008;44:301-322
54. Hert J, Irwin JJ, Laggner C, et al. Quantifying biogenic bias in screening libraries. Nat Chem Biol 2009;5:479-483
55. Maibaum J, Feldman DL. Case history on Tekturna®/Rasilez® (Aliskiren), a highly efficacious direct oral rennin inhibitor as a new therapy for hypertension. Ann Rep Med Chem 2008;44:105-127
56. David E, Tramontin T, Zemmel R. Pharmaceutical R&D: the road to positive returns. Nat Rev Drug Discov 2009;8:609-610
57. Ruffolo RR. Why has R&D productivity declined in the pharmaceutical industry? Exp Opin Drug Discov 2006;1:99-102